Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Triple Negative Breast Neoplasms 1Oropharyngeal Neoplasms 1

Interventions

Cisplatin 18Magnetic Resonance Spectroscopy 11Specimen Handling 9Radiotherapy, Intensity-Modulated 7Radiotherapy 7Radiation 7Carboplatin 7Platinum 5Chemoradiotherapy 51,2-diaminocyclohexaneplatinum II citrate 5Surgical Procedures, Operative 4Paclitaxel 4Docetaxel 4Biopsy 4pembrolizumab 3Surveys and Questionnaires 3toripalimab 2aldesleukin 2X-Rays 2Taxes 2Observation 2Interviews as Topic 2Immunohistochemistry 2Cetuximab 2Adoptive Transfer 2sacituzumab govitecan 1merphos 1ipatasertib 1human papillomavirus vaccine, TA 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Oropharyngeal Neoplasms × Vaccines, DNA × Clear all
NCT05799144 2025-10-22

pBI-11 & TA-HPV (With Pembrolizumab as Treatment for Patients w/Advanced, PD-L1 CPS≥1, hrHPV+ Oropharyngeal Cancer

Vanderbilt-Ingram Cancer Center

Phase 2 Recruiting
54 enrolled
Head & Neck

Oropharyngeal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡